Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Chronic myelogenous leukemia Stories

2013-11-18 08:27:51

Actinium Expects Single Trial Required for Regulatory Approval NEW YORK, Nov. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer, hosted a call on November 11, 2013 to discuss...

2013-11-11 08:28:05

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 11, 2013 /PRNewswire/ -- Dear Shareholders and Friends of DelMar Pharmaceuticals: I am pleased to provide you with an update as of the quarter ended September 30, 2013 and a summary of progress toward our goals for the year. Our Financials Are on BudgetAs of September 30, 2013 we have cash and equivalents of approximately $5.2 million. Our working capital balance is in line with our expectations. Based on our operating...

2013-11-01 16:23:48

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML). As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug. Those patients who are responding well to...

2013-10-24 23:03:21

The Cancer Support Community and The Leukemia & Lymphoma Society Partner on a Solution Washington, D.C. (PRWEB) October 24, 2013 The Cancer Support Community's Research and Training Institute and The Leukemia & Lymphoma Society (LLS) have joined forces to launch the Cancer Experience Registry: Chronic Myeloid Leukemia. According to LLS's Facts 2013 booklet, there will be 5,920 new cases of chronic myeloid leukemia (CML) diagnosed in the U.S. this year, making it a rare...

2013-10-21 08:29:07

VAL-083 therapeutic activity seen in glioblastoma, chronic myelogenous leukemia and non-small cell lung cancer VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 21, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. The data presented today, along with historical research by the U.S....

2013-10-08 09:44:05

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine. Chronic myeloid leukemia (CML) is an aggressive cancer of the blood that is often treated with a drug called Imatinib (a.k.a. Gleevec). Although Gleevec is highly effective, some cancer cells can develop resistance to the drug. The mechanism that drives this resistance is not completely understood, but there is evidence...

2013-09-23 23:04:49

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022. London (PRWEB) September 23, 2013 PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia...

2013-09-19 08:28:34

Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") today announced a discussion on CEOLIVE.TV by Jeffrey Bacha, president and CEO of DelMar Pharma, a cancer-focused company developing new therapies for patients with little to no treatment options....

2013-09-19 08:28:21

- CML community recognizes September 22 as World CML Day to raise awareness of the needs of patients living with CML EAST HANOVER, N.J., Sept. 19, 2013 /PRNewswire/ -- Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy - a concept called treatment-free...

2013-09-18 23:04:35

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...